evidenceId,evidenceType,shortDesc,desc,id,lastEdit,status,gene/entrezGeneId,gene/hugoSymbol,gene/name,gene/oncogene,gene/curatedIsoform,gene/curatedRefSeq,gene/geneAliases/0,gene/geneAliases/1,gene/geneAliases/2,gene/tsg,articles/0/pmid,articles/0/title,articles/0/journal,articles/0/pubDate,articles/0/volume,articles/0/issue,articles/0/pages,articles/0/authors,articles/0/elocationId,articles/0/link,articles/0/reference,articles/0/abstract,articles/1/pmid,articles/1/title,articles/1/journal,articles/1/pubDate,articles/1/volume,articles/1/issue,articles/1/pages,articles/1/authors,articles/1/elocationId,articles/1/link,articles/1/reference,articles/1/abstract,articles/2/pmid,articles/2/title,articles/2/journal,articles/2/pubDate,articles/2/volume,articles/2/issue,articles/2/pages,articles/2/authors,articles/2/elocationId,articles/2/link,articles/2/reference,articles/2/abstract,articles/3/pmid,articles/3/title,articles/3/journal,articles/3/pubDate,articles/3/volume,articles/3/issue,articles/3/pages,articles/3/authors,articles/3/elocationId,articles/3/link,articles/3/reference,articles/3/abstract,articles/4/pmid,articles/4/title,articles/4/journal,articles/4/pubDate,articles/4/volume,articles/4/issue,articles/4/pages,articles/4/authors,articles/4/elocationId,articles/4/link,articles/4/reference,articles/4/abstract
10043,GENE_BACKGROUND,,"PMS2 is an endonuclease that plays an essential role in the mismatch repair (MMR) pathway. Specifically, PMS2 nicks DNA to initiate excision of a mismatched strand (PMID: 20624957). Mutations in PMS2 lead to an inability to correctly repair mismatches and insertion/deletion loops in the DNA, which results in increased tumor hypermutation and a microsatellite instability high (MSI-H) phenotype (PMID: 14871975). Germline mutations of PMS2 can cause Lynch syndrome, which predisposes to certain cancers including colon, endometrial and ovarian cancers and implicates PMS2 as a tumor suppressor (PMID: 16472587). Sporadic PMS2 mutations have also been reported in cancers from numerous tissue types (PMID: 16472587). Tumor hypermutation has been associated with response to certain immunotherapies. Specifically, pembrolizumab has been FDA approved for all MMR-deficient and MSI tumors, irrespective of specific tumor etiology (PMID: 25409260, 26028255).",,2017-10-18,,5395,PMS2,"PMS1 homolog 2, mismatch repair system component",False,ENST00000265849,NM_000535.5,HNPCC4,PMSL2,MLH4,False,20624957,PMS2 endonuclease activity has distinct biological functions and is essential for genome maintenance.,Proceedings of the National Academy of Sciences of the United States of America,2018-07-27T20:10:00,107,30,13384-9,van Oers JM et al,doi: 10.1073/pnas.1008589107,,0001-07-27,,14871975,"Microsatellite instability, immunohistochemistry, and additional PMS2 staining in suspected hereditary nonpolyposis colorectal cancer.",Clinical cancer research : an official journal of the American Association for Cancer Research,2018-02-01T20:04:00,10,3,972-80,de Jong AE et al,,,0001-02-01,,25409260,Genetic basis for clinical response to CTLA-4 blockade in melanoma.,The New England journal of medicine,2017-12-04T20:14:00,371,23,2189-2199,Snyder A et al,doi: 10.1056/NEJMoa1406498,,0001-12-04,,16472587,Heterozygous mutations in PMS2 cause hereditary nonpolyposis colorectal carcinoma (Lynch syndrome).,Gastroenterology,2018-02-01T20:06:00,130,2,312-22,Hendriks YM et al,,,0001-02-01,,26028255,PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.,The New England journal of medicine,2018-06-25T20:15:00,372,26,2509-20,Le DT et al,doi: 10.1056/NEJMoa1500596,,0001-06-25,
10042,GENE_SUMMARY,,PMS2 encodes a tumor suppressor involved in DNA mismatch repair. Germline mutations of PMS2 are associated with Lynch Syndrome and predispose to colorectal cancer.,,2017-04-12,,5395,PMS2,"PMS1 homolog 2, mismatch repair system component",False,ENST00000265849,NM_000535.5,HNPCC4,PMSL2,MLH4,False,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
